Upstream / Downstream

Explore pathways related to this product.

Our U.S. Offices Will Be Closing Early

Our U.S. offices will be closing early on November 24th at 6:00 PM EST.

To Purchase # 8927SC

8927SC 10 µg (With Carrier) $199.00
8927SF 10 µg (Carrier Free) $199.00
8927LC 50 µg (With Carrier) $599.00
8927LF 50 µg (Carrier Free) $599.00
$ 0. 00

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant human IFN-α1 (hIFN-α1) Cys24 - Asp189 (Accession # NP_076918) was produced in E. coli at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIFN-α1. All lots are greater than 98% pure.


Molecular Formula:

Recombinant hIFN-α1 does not have a Met on the amino terminus and has a calculated MW of 19,386. DTT-reduced protein migrates as an 18 kDa polypeptide and non-reduced protein migrates as a 14 kDa polypeptide due to intramolecular cystines. The expected amino-terminal CDLPE of recombinant hIFN-α1 was verified by amino acid sequencing.


Bioactivity:

The bioactivity of hIFN-α1 was determined in a virus protection assay. The ED50 of each lot is between 20 - 60 pg/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1 μg hIFN-α1.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIFN-α1. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

Interferon-α1 is a member of the Type I IFN (1) family best known for their antiviral activity. Most nucleated cells produce one or more Type I IFNs in response to viral infection (2). Secreted Type I IFN then induces viral protective responses in neighboring non-infected cells. Type I IFNs also enhance virus-induced apoptosis (3). Other IFN-α1 activities include enhancement of dendritic cell maturation and cytotoxic T cell activity (4). IFN-α1 binds to the IFN-αR1 and IFN-αR2 heterodimer (1). Intracellular signaling through the Jak/Stat pathway is best characterized (3). However, the PI3K, ERK, and p38 kinase pathways are also involved (5). The antiviral activities of the IFNs have led to their use in treating viral infections (4). Type I IFNs also appear to have an integral role in several autoimmune diseases (6).


1.  Nagai, T. et al. (2003) J Immunol 171, 5233-43.

2.  Stetson, D.B. and Medzhitov, R. (2006) Immunity 25, 373-81.

3.  Vilcek, J. (2006) Immunity 25, 343-8.

4.  Luft, T. et al. (2002) Int Immunol 14, 367-80.

5.  van Boxel-Dezaire, A.H. et al. (2006) Immunity 25, 361-72.

6.  Banchereau, J. and Pascual, V. (2006) Immunity 25, 383-92.


Entrez-Gene Id 3439
Swiss-Prot Acc. P01562

Product Specific References

Voigt, E. et al. (2013) Virol J 10, 224.


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.